Endothelin and restenosis

Cardiovascular Research

Volumn 39, Issue 3, 1998, Pages 550-555

  Kirchengast, Michael ^a   Münter, Klaus ^a  

^a Knoll AG   (Germany)

Author keywords

Coronary angioplasty; Endothelin; Extracellular matrix; Restenosis; Smooth muscle cell proliferation

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ATRASENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; TAK 044; UNCLASSIFIED DRUG;

CORONARY ARTERY OBSTRUCTION; EXTRACELLULAR MATRIX; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; MOLECULAR DYNAMICS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SPECIES DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CORONARY DISEASE; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ENDOTHELINS; ENDOTHELIUM, VASCULAR; HUMANS; MITOGENS; MUSCLE, SMOOTH, VASCULAR; RATS; RECEPTORS, ENDOTHELIN; RECURRENCE; STENTS; SWINE; VASOCONSTRICTOR AGENTS;

EID: 0032168298     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00143-6     Document Type: Review

References (51)

1. Gruentzig A., Senning A., Siegenthaler W.E. Nonoperative dilatation of coronary artery stenosis. Percutaneous transluminal balloon angioplasty. New Engl J Med. 301:1979;61-68.
2. Anderson VH, Smalling RW, Serruys PW. Mechanical devices. In: Willerson JT, Cohn JN, editors. Cardiovascular Medicine. New York, Edinburgh, London: Churchill Livingstone, 1995:617-651.
3. Hillegass WB, Ohman EM, Califf RM. Restenosis: the clinical issues. In: Topol EJ, editor. Textbook of interventional cardiology. Philadelphia: WB Saunders, 1994:415-435.
4. Meyer B.J., Meier B., Bonzel T.et al. Interventional cardiology in Europe 1993. Eur Heart J. 17:1996;1318-1328.
5. Pratt R.E., Dzau V.E. Pharmacological strategies to prevent restenosis. Circulation. 93:1996;848-852.
6. Serruys P.W., de Jaegere P., Kiemeneij F.et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. New Engl J Med. 331:1994;489-495.
7. Fischman D.L., Leon M.B., Baim D.S.et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. New Engl J Med. 331:1998;496-501.
8. Schwartz R.S., Edwards W.D., Bailey K.R.et al. Differential neointimal response to coronary artery injury in pigs and dogs. Arterioscler Thromb. 14:1994;395-400.
9. Herrman J.-P.R., Hermans W.R.M., Vos J., Serruys P.W. Pharmacological approaches to the prevention of restenosis following balloon angioplasty. Drugs. 46:1993;18-52.
10. Bauters C., Meurice T., Hamon M.et al. Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovasc Res. 31:1996;835-846.
11. Liu M.W., Roubin G.S., King III S.B. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 79:1989;1374-1387.
12. Schwartz R.S., Holmes D.R., Topol E.J. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol. 20:1992;1284-1293.
13. Yanagisawa M., Kurihara H., Kimura S.et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
14. Rubanyi G.M., Polokoff M.A. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 46:1994;325-415.
15. Timm M., Kaski J.C., Dashwood M.R. Endothelin-like immunoreactivity in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol. 26:1995;S442-S444.
16. Zeiher A.M., Goebel H., Schächinger V., Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation. 91:1995;941-947.
17. Tahara A., Kohno M., Yanagi S.et al. Circulating immunoreactive endothelin in patients undergoing percutaneous transluminal coronary angioplasty. Metabolism. 40:1991;1235-1237.
18. Lerman A., Holmes D.R., Garratt K.N.et al. Local release of endothelin in human coronary arteries in response to balloon angioplasty (Abstract). J Am Coll Cardiol. 23:1994;124.
19. Resink T.J., Hahn A.W.A., Scott-Burden T.et al. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun. 168:1990;1303-1310.
20. B receptor mRNAs after balloon angioplasty in the rat. J Cardiovasc Pharmacol. 26:1995;S22-S25.
21. Minamino T., Kurihara H., Takahashi M.et al. Endothelin-converting enzyme expression in the rat vascular injury model and human coronary atherosclerosis. Circulation. 95:1997;221-230.
22. Bacon C.R., Davenport A.P. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol. 117:1996;986-992.
23. Dagassan P.H., Breu V., Clozel M.et al. Up-regulation of endothelin-B- receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol. 27:1996;147-153.
24. Wang X., Douglas S.A., Louden C.et al. Expression of endothelin-1, endothelin-3, endothelin-converting-enzyme-1, and endothelin-A and endothelin-B receptor mRNA after angioplasty-induced neointimal formation in the rat. Circ Res. 78:1996;322-328.
25. B receptors in the hyperplastic vascular wall. J Cardiovasc Pharmacol. 25:1995;802-809.
26. Dashwood M.R., Münter K., Kirchengast M. Endothelin-1 (ET-1) and its receptors in porcine coronary artery: Effect of balloon angioplasty (Abstract). J Mol Cell Cardiol. 29:1997;242.
27. A receptor antagonist, LU 135252. Circ Res. 1998; in press.
28. Kanse S.M., Wijelath E., Kanthou C., Newman P., Kakkar V.V. The proliferative responsiveness of human vascular smooth muscle cells to endothelin correlates with endothelin receptor density. Lab Invest. 72:1995;76-82.
29. Weber H., Webb M.L., Serafino R.et al. Endothelin-1 and angiotensin II stimulate delayed mitogenesis in cultured rat smooth muscle cells-Evidence for common signalling mechanisms. Mol Endocrinol. 8:1994;148-158.
30. + exchange activation by endothelin in vascular smooth muscle cells. Am J Hypertens. 4:1991;776-779.
31. Rizvi M.A.D., Katwa L.C., Spadone D.P., Myers P.R. The effects of endothelin-1 on collagen type I and type III synthesis in cultured procine coronary artery vascular smooth muscle cells. J Mol Cell Cardiol. 28:1996;243-252.
32. Douglas S.A., Ohlstein E.H. Endothelin-1 promotes neointima formation after balloon angioplasty in the rat. J Cardiovasc Pharmacol. 22:1993;S371-S373.
33. Trachtenberg J.D., Sun S., Choi E.T., Callow A.D., Ryan U.S. Effect of endothelin-1 infusion on the development of intimal hyperplasia after balloon catheter injury. J Cardiovasc Pharmacol. 22:1993;S355-S359.
34. Battistini B., Chailler P., D'Orléans-Juste P., Briére N., Sirois P. Growth regulatory properties of endothelins. Peptides. 14:1993;385-399.
35. Pedram A., Razandi M., Hu R.-M., Levin E.R. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem. 272:1997;17097-17103.
36. A-receptor antagonist. Circulation. 96:1997;1593-1597.
37. Schini V.B., Hendrickson H., Heublein D.M., Burnett J.C., Vanhoutte P.M. Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. Eur J Pharmacol. 165:1989;333-334.
38. Boulanger C.M., Lüscher T.F. Hirudin and nitrates inhibit the thrombin-induced release of endothelin from the intact porcine aorta. Circ Res. 68:1991;1768-1772.
39. Willerson J.T., Yao S.-K., McNatt J.et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA. 88:1991;10624-10628.
40. B-receptor antagonism in a locally injured canine coronary artery. Eur J Pharmacol. 341:1998;187-190.
41. A receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the rat. Cardiovasc Res. 29:1995;641-646.
42. Douglas S.A., Louden C., Vickery-Clark L.M.et al. A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Circ Res. 75:1994;190-197.
43. Ferrer P., Valentine M., Jenkins-West T.et al. Orally active endothelin receptor antagonist BMS-182874 suppresses neointimal development in balloon-injured rat carotid arteries. J Cardiovasc Pharmacol. 26:1995;908-915.
44. B receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty. Life Sci. 56:1995;PL449-PL454.
45. A receptor antagonist FR 139317 inhibits neointimal thickening in the rat. Eur J Pharmacol. 309:1996;59-62.
46. A-receptor antagonist inhibits neointima formation induced by endothelial injury. Pharm Pharmacol Lett. 6:1996;90-92.
47. B receptor antagonists inhibit balloon catheter-induced smooth muscle cell proliferation in the rat thoracic aorta (Abstract). Br J Pharmacol. 114:1995;199.
48. A receptor reduces neointimal hyperplasia after balloon-induced injury in pigs. J Cardiovasc Pharmacol. 30:1997;33-41.
49. A receptor antagonism reduces neointimal hyperplasia in a porcine coronary stent model (Abstract). J Am Coll Cardiol. 31:1998;1063. (Abstract).
50. A) receptor antagonist LU 135252 (P610: Abstract). Eur Heart J. 18:1997;87.
51. Krum H., Viskoper R.J., Lacourciere Y.et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. New Engl J Med. 338:1998;784-790.